MedTrace Logo

Duobrii in Combination With Biologics

NCT04119102 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2020-04-30

No results posted yet for this study

Summary

12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks

Conditions

Interventions

DRUG

Duobrii

duobrii applied daily for 4 weeks followed by every other day for 4 weeks.

Sponsors & Collaborators

  • Ortho Dermatologics

    collaborator INDUSTRY

  • Psoriasis Treatment Center of Central New Jersey

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-14
Primary Completion
2020-08-01
Completion
2020-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04119102 on ClinicalTrials.gov